TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake

Rhea-AI Filing Summary

TYRA Biosciences, Inc. received an amended Schedule 13G filing reporting the ownership of a Nextech-managed investment vehicle and related parties. Nextech VI Oncology SCSp beneficially owns 3,553,585 shares of TYRA common stock as of June 30, 2026, representing 6.0% of the class, based on 59,470,381 shares outstanding as of May 8, 2026. Nextech VI GP S.a. r.l. is the sole general partner of Nextech VI Oncology SCSp, and Ian Charoub, Costas Constantinides, and Rocco Sgobbo serve on the GP’s board of managers, with power to direct voting and disposition of these shares. The reporting persons expressly disclaim status as a group for ownership reporting purposes.

Key Figures

Beneficially owned shares: 3,553,585 shares Ownership percentage: 6.0% Shares outstanding: 59,470,381 shares +1 more

4 metrics

Beneficially owned shares 3,553,585 shares Shares of TYRA common stock beneficially owned by Nextech VI Oncology SCSp as of June 30, 2026

Ownership percentage 6.0% Percentage of TYRA common stock class beneficially owned by each reporting person

Shares outstanding 59,470,381 shares TYRA common shares outstanding as of May 8, 2026, used to calculate ownership percentage

CUSIP 90240B106 CUSIP number for TYRA Biosciences, Inc. common stock

Key Terms

beneficially owned, sole voting power, dispositive power, Schedule 13G, +1 more

5 terms

beneficially owned financial

"sets forth the aggregate number of shares of common stock of the Issuer beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Row 5 of each Reporting Person's cover page sets forth the sole voting power"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"sole power to dispose or to direct the disposition of securities of the Issuer"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"Exhibit 99.1 Joint Filing Agreement incorporated by reference to the Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Reporting Persons regulatory

"The names of the persons filing this report (collectively, the "Reporting Persons") are"

FAQ

What ownership stake in TYRA (TYRA) does Nextech VI Oncology SCSp report?

Nextech VI Oncology SCSp reports beneficial ownership of 3,553,585 shares of TYRA Biosciences common stock. This represents 6.0% of the outstanding shares, based on 59,470,381 shares outstanding as of May 8, 2026.

Who are the reporting persons in this TYRA (TYRA) Schedule 13G/A amendment?

The reporting persons are Nextech VI Oncology SCSp, Nextech VI GP S.a. r.l., and individuals Ian Charoub, Costas Constantinides, and Rocco Sgobbo. They collectively report on the same 3,553,585 TYRA shares.

What percentage of TYRA (TYRA) common stock is reported as beneficially owned?

The filing states a beneficial ownership of 6.0% of TYRA’s common stock. This percentage is calculated using 59,470,381 shares outstanding as of May 8, 2026, as reported in TYRA’s Form 10-Q.

Who has voting and dispositive power over the TYRA (TYRA) shares reported?

Nextech VI Oncology SCSp holds the 3,553,585 shares, while Nextech VI GP and its managers Charoub, Constantinides, and Sgobbo have power to direct the voting and disposition of those TYRA shares.

Does the TYRA (TYRA) Schedule 13G/A state that the reporting persons form a group?

No. The filing states that the reporting persons expressly disclaim status as a “group” for ownership reporting purposes, even though they jointly report beneficial ownership of the same TYRA shares.

As of what dates are the TYRA (TYRA) ownership figures in this filing measured?

The 3,553,585 shares beneficially owned are measured as of June 30, 2026. The 6.0% ownership is based on 59,470,381 shares outstanding as of May 8, 2026, referenced from TYRA’s Form 10-Q.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:45 PM Accepted by SEC EDGAR 08/14/2026 - 04:44 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

TYRA BIOSCIENCES, INC.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

90240B106

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Nextech VI Oncology SCSp

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,553,585.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,553,585.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,553,585.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Nextech VI GP S.a. r.l.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,553,585.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,553,585.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,553,585.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Ian Charoub

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWEDEN

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,553,585.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,553,585.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,553,585.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Costas Constantinides

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CYPRUS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,553,585.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,553,585.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,553,585.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Rocco Sgobbo

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,553,585.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,553,585.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,553,585.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TYRA BIOSCIENCES, INC.
(b)	Address of issuer's principal executive offices: 2656 State Street, Carlsbad, CA, 92008.
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") are: Nextech VI Oncology SCSp ("Nextech VI LP") Nextech VI GP S.a. r.l. ("Nextech VI GP") Ian Charoub ("Charoub") Costas Constantinides ("Constantinides") Rocco Sgobbo ("Sgobbo") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)	Address or principal business office or, if none, residence: Bahnhofstrasse 18 Zurich, Switzerland 8001
(c)	Citizenship: Nextech VI LP Luxembourg Nextech VI GP Luxembourg Charoub Sweden Constantinides Cyprus Sgobbo Switzerland
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP No.: 90240B106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference. Nextech VI LP holds 3,553,585 shares of common stock of the Issuer. Nextech VI GP serves as the sole general partner of Nextech VI LP and Charoub, Constantinides and Sgobbo are members of the board of managers of Nextech VI GP. Each of Nextech VI GP, Charoub, Constantinides and Sgobbo possesses power to direct the voting and disposition of the securities held by Nextech VI LP.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 59,470,381 shares of common stock outstanding as of May 8, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 13, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nextech VI Oncology SCSp

Signature:	/s/ Ian Charoub
Name/Title:	By Nextech VI GP S.a r.l., its General Partner, By Ian Charoub, Manager
Date:	08/14/2026

Signature:	/s/ Costas Constantinides
Name/Title:	By Nextech VI GP S.a r.l., its General Partner, By Costas Constantinides, Manager
Date:	08/14/2026

Nextech VI GP S.a. r.l.

Signature:	/s/ Ian Charoub
Name/Title:	By Ian Charoub, Manager
Date:	08/14/2026

Signature:	/s/ Costas Constantinides
Name/Title:	By Costas Constantinides, Manager
Date:	08/14/2026

Ian Charoub

Signature:	/s/ Ian Charoub
Name/Title:	Ian Charoub
Date:	08/14/2026

Costas Constantinides

Signature:	/s/ Costas Constantinides
Name/Title:	Costas Constantinides
Date:	08/14/2026

Rocco Sgobbo

Signature:	/s/ Rocco Sgobbo
Name/Title:	Rocco Sgobbo
Date:	08/14/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Schedule 13G filed by the Reporting Persons with the SEC on November 14, 2024).